This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
HSPG2 / Basement membrane-specific heparan sulfate proteoglycan core protein · IHC design guide
Design Immunohistochemistry for HSPG2
Plan chromogenic IHC on paraffin sections using the human-reactive catalog antibody at 0.5–1 μg/ml (datasheet: PB9277). Interpret cytoplasmic and extracellular matrix staining in light of the tissue IHC profile and HSPG2 processing (HPA tissue IHC; UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
HSPG2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and extracellular matrix staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic signal, including endothelium; ECM positivity (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Heart muscle | |
| Negative control | Adrenal gland+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Secretion can complicate RNA–protein agreement (HPA tissue IHC) | |
| Regulation | Blood vessel–enhanced tissue RNA (HPA tissue RNA) | |
| Isoform / epitope | No isoforms listed; C-terminal fragments affect epitope mapping (UniProt) |
Section 1
Recommended HSPG2 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with published HSPG2 stains of human plaques and kidney (PMC7508285; PMC12747916).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet PB9277); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-HSPG2, 0.5-1μg/ml (datasheet PB9277) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | HSPG2-positive staining in cardiomyocytes of heart muscle (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in several tissue types, including endothelial cells. Positivity in extracellular matrix. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page antigen-retrieval setting); both published protocols also used citrate retrieval (PMC7508285; PMC12747916).
Section 2
What Is the Expected HSPG2 Staining Pattern?
HSPG2 (perlecan) is secreted into extracellular matrix and basement membranes, with no transmembrane segment (UniProt P98160: location and topology). In paraffin-section IHC, expect extracellular-matrix positivity and possible cytoplasmic staining, including endothelial cells (HPA tissue IHC: Approved; expression profile). Heart-muscle cardiomyocytes provide a documented medium-intensity positive example (HPA tissue IHC: Heart muscle). HPA cautions that protein and RNA locations may differ for a secreted protein (HPA tissue IHC: reliability description).
| Matrix or basement-membrane staining, with cytoplasmic staining in endothelial cells or cardiomyocytes. | This fits the reported extracellular-matrix and endothelial pattern (HPA tissue IHC: expression profile) and the medium cardiomyocyte signal in heart muscle (HPA tissue IHC: Heart muscle). Assess extracellular and cellular compartments separately: secreted HSPG2 can remain around cells after release (UniProt P98160: secreted, extracellular matrix). |
| Strong, isolated nuclear staining with little corresponding extracellular or cytoplasmic signal. | Treat this as a localization mismatch requiring a specificity check: the supplied locations are secreted and extracellular, with no nuclear location reported (UniProt P98160: location and topology; HPA tissue IHC: expression profile). Review the no-primary control and compare staining from another IHC-approved antibody before assigning the nuclear signal to HSPG2 (general IHC practice; HPA antibodies: IHC Approved). |
| Strong cellular staining in a population reported as not detected, such as adrenal glandular cells. | This conflicts with the stated cell-type observation, though it does not rule out staining in nearby matrix (HPA tissue IHC: Adrenal gland, glandular cells; HPA tissue IHC: extracellular-matrix positivity). Check whether the chromogen also appears in a no-primary control; persistent staining there can reflect endogenous detection activity (general IHC practice). |
| Broad, low-contrast chromogen across many cells and extracellular spaces. | Diffuse signal without a discernible compartment cannot establish the reported HSPG2 pattern (HPA tissue IHC: expression profile). Evaluate the no-primary control, blocking and wash conditions, and detection background; these are general IHC checks, not evidence of an HSPG2-specific fixation or retrieval effect (general IHC practice). |
| No visible staining in the heart-muscle cardiomyocytes used as a positive reference. | HPA reports medium cardiomyocyte expression, so a blank reference slide leaves the run unresolved (HPA tissue IHC: Heart muscle). Check section integrity, antibody and detection steps, and the chosen retrieval conditions using the antibody's IHC instructions (general IHC practice). A failed reference does not establish biological absence of HSPG2. |
💡Expected HSPG2 appearanceCall a result consistent when extracellular matrix or basement membranes stain and heart-muscle cardiomyocytes show approximately medium signal, while isolated nuclear staining or chromogen in a no-primary control prompts review (UniProt P98160: location; HPA tissue IHC: expression profile and Heart muscle; general IHC practice).
| Secreted protein and cellular signal | HSPG2 is secreted into basement membranes and extracellular matrix (UniProt P98160: location). HPA also reports cytoplasmic expression, including endothelial cells (HPA tissue IHC: expression profile). Interpret those compartments together; cellular signal alone does not show where the released protein accumulates. |
| Antibody epitope and processing | The precursor has a signal peptide at residues 1–21; its C-terminal region includes endorepellin and LG3 (UniProt P98160: processing). The supplied antibody records give no epitope positions (HPA antibodies: supplied validation records), so staining with a particular antibody cannot be assigned to a specific processed region. |
| Heparan-sulfate proteoglycan structure | HSPG2 is a glycoprotein and heparan-sulfate proteoglycan with listed glycosylation sites (UniProt P98160: keywords and glycosylation). These annotations describe the molecule; they do not establish an antigen-retrieval requirement or predict the intensity of an individual IHC slide. |
| IHC evidence and tissue selection | The tissue profile is Approved, and four listed antibodies have Approved IHC status (HPA tissue IHC: reliability; HPA antibodies: IHC status). Heart-muscle cardiomyocytes are a documented positive reference; a listed cell type with no detected staining is a compartment-specific comparison, not proof that its whole tissue lacks extracellular HSPG2 (HPA tissue IHC: Heart muscle and negative cell entries). |
| IF/ICC? | No cell line images or main intracellular location are supplied for ICC-IF, and the listed antibodies have no ICC validation entry (HPA subcellular: image list and main location; HPA antibodies: ICC status). For IF/ICC interpretation, use the secreted extracellular location as biological context without assigning a validated cell-line pattern (UniProt P98160: location). |
| Situation | Likely cause | Next action |
|---|---|---|
| Heart-muscle reference is blank. | The run may have failed at staining or detection; HPA reports medium cardiomyocyte signal (HPA tissue IHC: Heart muscle). | Confirm tissue is present and the control run worked, then review antibody, retrieval and detection steps against the IHC instructions (general IHC practice). Do not score test sections from an unresolved run. |
| Only nuclear staining is prominent. | Nuclear localization conflicts with the supplied secreted and extracellular assignments (UniProt P98160: location; HPA tissue IHC: expression profile). | Check a no-primary control and compare the compartment pattern with an independent IHC-approved antibody where available (general IHC practice; HPA antibodies: IHC Approved). Report the discrepancy rather than scoring nuclear signal as expected HSPG2. |
| Chromogen appears in the no-primary control. | Detection-system or tissue-derived activity can produce color without the primary antibody (general IHC practice). | Resolve the control background before interpreting cellular positivity; review detection reagents and, when using an enzyme-based system, the relevant endogenous-activity blocking step (general IHC practice). |
| Adrenal glandular cells stain strongly. | HPA lists these cells as not detected, although extracellular matrix may stain nearby (HPA tissue IHC: Adrenal gland, glandular cells; expression profile). | Separate glandular-cell signal from surrounding matrix under the microscope, then inspect the no-primary control and an IHC-approved comparator if available (general IHC practice; HPA antibodies: IHC Approved). |
| Most of the section has diffuse, weak color. | The pattern lacks the compartment contrast needed to recognize reported matrix and endothelial staining (HPA tissue IHC: expression profile). | Assess background on the no-primary control and review blocking, washes and detection conditions (general IHC practice). Avoid calling the diffuse color HSPG2-positive until anatomical structures can be distinguished. |
| A negative cell population is used to judge the whole section. | HPA's not detected entries name specific cell types, while its overall profile reports extracellular-matrix positivity (HPA tissue IHC: negative cell entries and expression profile). | Score the named cells and adjacent matrix separately; use the documented heart-muscle cardiomyocyte signal as a positive reference for the run (HPA tissue IHC: Heart muscle). |
Experiment evidence
IHC & IF images showing HSPG2 staining
PB9277 · IHCAnti-HSPG2 vendor antibody, PB9277,IHC(P) IHC(P): Human Lung Cancer Tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000142798-HSPG2/tissue/cerebral+cortex#imid_3656472
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000142798-HSPG2/tissue/colon#imid_3656398
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000142798-HSPG2/tissue/liver#imid_3656415
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000142798-HSPG2/tissue/kidney#imid_3656400
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for HSPG2 IHC & IF
🧪Run heart muscle first and assess cardiomyocyte-associated staining, reported at Medium level (HPA: Medium in cardiomyocytes). Use adrenal gland glandular cells as the negative comparison (HPA: Not detected in adrenal gland glandular cells); on the heart slide, nuclei should lack specific signal, while extracellular basement membrane staining may be present (UniProt P98160: extracellular matrix and basement membrane localization).
Positive control tissue: Heart muscle (Cardiomyocytes, HPA Medium)
Negative control tissue: Adrenal gland (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for HSPG2; derive a cell-line control from the positive tissue's cell type (Cardiomyocytes) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary (secondary-only) slide, an irrelevant IgG control matched to the primary antibody’s host species and antibody class, and HSPG2 knockout tissue or a validated peptide-block control where available (standard IHC specificity controls). For chromogenic heart sections, quench endogenous peroxidase and inspect the no-primary slide for residual signal (standard IHC practice; HPA: heart muscle positive tissue).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported in the supplied evidence; the selected PB9277 paraffin-section caption also leaves the fixative unreported (PB9277 tissue-IHC caption: fixative not stated). Antigen retrieval requirements are unreported, so assess retrieval conditions on the heart positive control; the evidence does not establish that frozen sections or IF are easier, and HPA lists no ICC-IF image-bearing cell lines (HPA subcellular: no ICC-IF cell lines). Interpret heart staining with its extracellular basement membrane location in mind, and check for residual endogenous peroxidase signal (UniProt P98160: basement membrane localization; standard IHC practice).
HPA tissue IHC evidence for HSPG2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Heart muscle | Cardiomyocytes | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Cerebral cortex | Glial cells | Not detected | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced HSPG2 IHC Tips
Troubleshoot HSPG2 staining by evaluating basement membrane patterns, epitope accessibility, background and compartment specific scoring.
How should I retrieve HSPG2 in paraffin sections when staining is weak?
Start with citrate buffer at pH 6.0 for heat induced epitope retrieval at 95–98 °C for 20 min (page retrieval setting). Compare retrieved and unretrieved serial sections, keeping antibody concentration and chromogen development constant so any gain can be attributed to retrieval (standard IHC practice). If staining remains weak, test a higher pH retrieval buffer on adjacent sections as a fallback, while checking whether tissue morphology and background deteriorate (standard IHC practice). Score linear basement membrane staining separately from cellular staining because HSPG2 is an extracellular matrix protein and HPA also reports cytoplasmic positivity (UniProt P98160 localisation; HPA tissue IHC).
Could fixation explain weak or uneven HSPG2 staining?
Target specific fixation sensitivity is unknown from the supplied evidence; the PB9277 tissue caption identifies an IHC(P) image but does not state its fixative (PB9277 tissue IHC caption). Record the actual fixative, fixation duration and processing history for each section before comparing staining across specimens (standard IHC practice). On adjacent sections, keep retrieval at citrate pH 6.0, 95–98 °C for 20 min and hold detection conditions constant (page retrieval setting; standard IHC practice). Check whether weak staining follows processing batches or appears within a section, and assess morphology alongside signal before changing the protocol (standard IHC practice).
Which HSPG2 staining compartments should I expect in tissue?
Prioritise extracellular, linear staining along basement membranes because HSPG2 is secreted into the extracellular matrix and has no transmembrane segment (UniProt P98160 localisation and topology). HPA also reports cytoplasmic expression in several tissue types, including endothelial cells, alongside extracellular matrix positivity (HPA tissue IHC). Examine tissue architecture and compare the distribution with an adjacent section stained for a basement membrane component, such as collagen IV, when compartment assignment is uncertain (UniProt P98160 subunit; standard IHC practice). Document cellular and extracellular signal separately; a cytoplasmic pattern alone cannot establish that intact perlecan is retained inside cells (HPA tissue IHC; UniProt P98160 localisation).
Why might antibodies to different HSPG2 epitopes produce different patterns?
The supplied record lists no isoforms but identifies a 22–4391 core protein chain, 3687–4391 endorepellin and 4197–4391 LG3 peptide (UniProt P98160 processing). An antibody against a C terminal region could therefore detect a processed region as well as an intact core protein, depending on its validated epitope (UniProt P98160 processing; standard antibody interpretation). HSPG2 has 18 listed glycosylation sites, so epitope accessibility should be assessed empirically rather than assumed from sequence alone (UniProt P98160 glycosylation; standard IHC practice). Compare documented epitope regions and staining compartments on adjacent sections before interpreting discordant patterns as different isoforms (UniProt P98160 isoforms and localisation; standard IHC practice).
How can I adapt the localisation check to multiplex IF?
For multiplex IF, pair HSPG2 with a basement membrane marker such as collagen IV and, when endothelial association is the question, an endothelial marker (UniProt P98160 subunit; HPA tissue IHC; standard IF practice). Select fluorophores after examining an unstained section for autofluorescence, and place the weaker signal in a channel with better separation from that background (standard IF practice). Because HSPG2 is secreted and lacks a transmembrane segment, begin without detergent permeabilisation for accessible extracellular epitopes; assess permeabilisation separately if testing reported cytoplasmic signal (UniProt P98160 localisation and topology; HPA tissue IHC; standard IF practice). Validate each channel singly before interpreting overlap, since adjacent extracellular and cellular signals can appear coincident (standard IF practice).
How do I distinguish diffuse HSPG2 signal from chromogenic background?
Run a no primary control through the same secondary antibody and chromogen steps, and inspect edges, folds and damaged areas before attributing diffuse colour to HSPG2 (standard IHC practice). Include a peroxidase block when using horseradish peroxidase and DAB detection, and compare sections developed for the same duration (standard IHC practice). Titrate the primary antibody empirically rather than assigning an unsupported dilution; excessive concentration can raise nonspecific staining (standard IHC practice). Retain staining that follows coherent basement membrane structures as a candidate signal, while checking diffuse cellular deposits against the control and HPA’s reported cytoplasmic pattern (UniProt P98160 localisation; HPA tissue IHC; standard IHC practice).
What should I measure when HSPG2 stains both matrix and cells? ⚠ ANSWER MARKED FOR VERIFICATION
Define separate regions for basement membrane and cellular staining before scoring, because HSPG2 is extracellular but HPA also reports cytoplasmic positivity (UniProt P98160 localisation; HPA tissue IHC). For matrix, measure stained length or area per mm² of evaluable tissue, or normalise signal to the length of the relevant basement membrane (standard image analysis practice). For a specified cell population, report percent positive cells or an H score, using identical intensity thresholds and a stated denominator across specimens (standard IHC scoring practice). Exclude folds and necrotic regions, and keep retrieval, illumination and DAB development consistent when comparing slides (standard IHC practice).
When is an apparent HSPG2 positive pattern likely to be artefactual?
A continuous extracellular pattern following basement membranes is consistent with HSPG2 localisation, whereas isolated nuclear signal would conflict with its secreted extracellular annotation (UniProt P98160 localisation and topology). Do not dismiss all cellular colour: HPA reports cytoplasmic expression, including in endothelial cells, so assess its anatomy and control staining (HPA tissue IHC; standard IHC practice). Suspect artefact when colour concentrates at section edges, folds or necrotic areas, or appears in the no primary control after peroxidase based detection (standard IHC practice). Resolve ambiguous staining with serial sections, a matched control and separate scoring of matrix and cells; the PB9277 caption documents human lung cancer tissue IHC(P) without reporting fixation (PB9277 tissue IHC caption; standard IHC practice).
Boster reagents
Best HSPG2 / Basement membrane-specific heparan sulfate proteoglycan core protein IHC Antibodies
PB9277 has human IHC(P) data from lung cancer tissue (catalog: Human, IHC; PB9277 IHC image caption: human lung cancer tissue). No IF image is listed (catalog: IF images).
Real IHC data
Anti-Heparan Sulfate Proteoglycan 2/HSPG2 Antibody ®
Cat # PB9277
PB9277 is the only SKU listed, with Human reactivity and IHC and WB applications (catalog: PB9277 applications, reactivity). Its own IHC(P) image shows human lung cancer tissue; no IF image is listed (PB9277 IHC image caption; catalog: IF images).
Which to pick: Choose PB9277 for human paraffin-section tissue IHC based on its IHC application listing and its own IHC(P) image caption (catalog: PB9277 applications; PB9277 IHC image caption). The caption does not report the fixative (PB9277 IHC image caption). No listed SKU supports an IF/ICC or cross-species recommendation: PB9277 lists Human and IHC/WB only, has no IF image, and has unspecified clonality (catalog: PB9277 reactivity, applications, IF images, clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P98160 (PGBM_HUMAN, Basement membrane-specific heparan sulfate proteoglycan core protein).
- Human Protein Atlas. HSPG2 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. HSPG2 subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. HSPG2 antibody validation summary (4 antibodies).
- Parallel Murine and Human Plaque Proteomics Reveals Pathways of Plaque Rupture. Circulation research 2020 — PMC7508285.
- Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. Frontiers in immunology 2018 — PMC6174292.
- Vascular gene expression patterns are conserved in primary and metastatic brain tumors. Journal of neuro-oncology 2010 — PMC2904485.
- Single-cell analysis reveals shared adaptive responses across different types of podocyte injury. Frontiers in immunology 2025 — PMC12747916.
- PubMed PMID:1569102 — UniProt-cited evidence.
- PubMed PMID:1730768 — UniProt-cited evidence.
- PubMed PMID:16710414 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for HSPG2 (Basement membrane-specific heparan sulfate proteoglycan core protein). Expected localisation Cytoplasmic and extracellular matrix staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: PB9277 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Heart muscle (Cardiomyocytes); negative Adrenal gland. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet PB9277); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-HSPG2, 0.5-1μg/ml (datasheet PB9277); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Secretion can complicate RNA–protein agreement (HPA tissue IHC); Isoform / epitope: No isoforms listed; C-terminal fragments affect epitope mapping (UniProt); Regulation: Blood vessel–enhanced tissue RNA (HPA tissue RNA). Evidence: UniProt P98160, HPA tissue IHC · Approved, HPA ICC-IF · Secreted, Datasheet PB9277, PMC7508285, PMC12747916. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/HSPG2/immunohistochemistry-ihc-guide.